scholarly journals Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines.

1998 ◽  
Vol 101 (9) ◽  
pp. 1876-1880 ◽  
Author(s):  
L B Margolis ◽  
S Glushakova ◽  
J C Grivel ◽  
P M Murphy
Keyword(s):  
Human Immunodeficiency Virus ◽  
Chemokine Receptor ◽  
Lymphoid Tissue ◽  
Cc Chemokine ◽  
Immunodeficiency Virus ◽  
Cc Chemokines ◽  
Human Lymphoid Tissue ◽  
Cc Chemokine Receptor 5 ◽  
Human Immunodeficiency Virus 1 ◽  
Chemokine Receptor 5

scholarly journals CC Chemokine Receptor 5 Genotype and Susceptibility to Transmission of Human Immunodeficiency Virus Type 1 in Women

2003 ◽  
Vol 187 (4) ◽  
pp. 569-575 ◽  
Author(s):  
Sean Philpott ◽  
Barbara Weiser ◽  
Patrick Tarwater ◽  
Sten H. Vermund ◽  
Cynthia A. Kleeberger ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Chemokine Receptor ◽  
Cc Chemokine ◽  
Immunodeficiency Virus ◽  
Cc Chemokine Receptor 5 ◽  
Chemokine Receptor 5

Obstacles and options in the quest for drug candidates against vascular disease

2010 ◽  
Vol 104 (07) ◽  
pp. 1-3 ◽  
Author(s):  
Christian Weber
Keyword(s):  
Metabolic Disease ◽  
Human Immunodeficiency Virus ◽  
Clinical Trials ◽  
Chemokine Receptor ◽  
Drug Candidates ◽  
Immunodeficiency Virus ◽  
Aging Populations ◽  
Ccr5 Antagonists ◽  
Cc Chemokine Receptor 5 ◽  
Human Immunodeficiency Virus 1

Summaryhe difficulties in cardiovascular drug development have been exposed by recent clinical trials, which have uncovered various limitations of promising drug candidates. Yet, the imperative to improve medical treatment of atherosclerosis in aging populations afflicted by metabolic disease remains unbroken. Herein alternatives to metabolically active compounds such as glitazones and torcetrapib are introduced and discussed, namely CC chemokine receptor 5 (CCR5) antagonists recently approved for treatment of patients with human immunodeficiency virus-1, interceptors of proatherogenic chemokine interactions, and actively protective pathways. A combination of different strategies may yield improved safety profiles of these therapeutics.

Discovery of Bioavailable 4,4-Disubstituted Piperidines as Potent Ligands of the Chemokine Receptor 5 and Inhibitors of the Human Immunodeficiency Virus-1

2008 ◽  
Vol 51 (20) ◽  
pp. 6538-6546 ◽  
Author(s):  
Wieslaw M. Kazmierski ◽  
Christopher Aquino ◽  
Brian A. Chauder ◽  
Felix Deanda ◽  
Robert Ferris ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Chemokine Receptor ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1 ◽  
Chemokine Receptor 5
Sign in / Sign up

Export Citation Format

Share Document